NCT06710366 (DAO-NEO-2022) is a clinical trial in DAO Genetic Variants, sponsored by AB Biotek.

Who is sponsoring NCT06710366?

NCT06710366 is sponsored by AB Biotek.

What condition does NCT06710366 study?

NCT06710366 studies DAO Genetic Variants.

Is NCT06710366 still recruiting?

NCT06710366 is currently completed. Last updated 29 November 2024.

Last reviewed 2024-11-29 · How we verify

NCT06710366: DAO-NEO-2022

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevalence of DAO (diamino Oxidase) Deficiency in Newborns

Completed Last updated 29 November 2024

What this trial tests

trial in DAO Genetic Variants in 200 participants. Completed in 26 June 2024.

Timeline

28 February 2023

Primary endpoint
21 June 2024

26 June 2024

Quick facts

Lead sponsor	AB Biotek
Status	Completed
Study type	OBSERVATIONAL
Enrollment	200
Start date	28 February 2023
Primary completion	21 June 2024
Estimated completion	26 June 2024
Sites	1 location across Spain

Conditions studied

DAO Genetic Variants — all drugs for DAO Genetic Variants →

Sponsor

AB Biotek

Who can join

Adults 0 Days to 3 Days, any sex, with DAO Genetic Variants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational study to estimate the prevalence of genetic DAO deficiency in the population.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Prevalence of Single Nucleotide Polymorphisms of the <i>AOC1</i> Gene Associated with Diamine Oxidase (DAO) Enzyme Deficiency in Healthy Newborns: A Prospective Population-Based Cohort Study.
Fortes Marin E, Carrera Marcolin L, Martí Melero L, Tintoré Gazulla M, et al · · 2025 · cited 4× · PMID 40004469 · DOI 10.3390/genes16020141

Verify or expand the search:

Other AB Biotek trials

Trials by the same sponsor.

NCT06715163 — Evaluation of the Safety and Tolerability of Three Doses of Diamine Oxidase (DAO) in Healthy Volunteers · NA · completed
NCT07027943 — Evaluation Of The Diamine Oxidase Supplementation Effect In Patients With Insomnia Symptoms · NA · completed
NCT07006558 — Kinetic Study Of Supplementation With The Enzyme Diamine Oxidase In Patients With Histamine Intolerance · NA · completed
NCT06488027 — DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS · completed
NCT06738433 — Efficacy and Tolerability of ABB I5 Prebiotic and ABB C22 Postbiotics for the Management of Constipation and Gastrointes · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06710366 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AB Biotek
Last refreshed: 29 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06710366.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing